Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

PharmaBio Corporation

Status

Enrolling

Conditions

Myopic Chorioretinal Atrophy

Treatments

Procedure: Pars plana vitrectomy

Study type

Interventional

Funder types

Industry

Identifiers

NCT05658237

PAL-222-P1

Details and patient eligibility

About

The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy.

The main question it aims to answer are:

• Percentage of changes in the chorioretinal atrophic area

Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy.

Researchers will compare non-therapeutic eye to see if the changes is significant different.

Enrollment

10 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged 20 years or older at the time of consent acquisition
Patients with binocular intensity myopia (myopia of -6.0 diopter (D) or more) or patients with axial length (26 mm) or more equivalent to -6.0 D
Corrected characters of the test eye patients with visual acuity of less than 60 characters (equivalent to decimal visual acuity 0.32)
Patients diagnosed with binocular myopic chorioretinal atrophy and having atrophy of 1 papillary diameter (1.5 mm) or more in the area within 2 papillary diameter (3.0 mm) including the fovea centralis in the subject eye
Patients without active choroidal neovascularization

Exclusion criteria

Patients with abnormal findings that pose a problem in clinical trial participation in screening tests.
Patients with positive hepatitis B surface (HBs) antigen, Hepatitis C virus (HCV) antibody, Human immunodeficiency virus (HIV) antibody, Human T-lymphotropic virus type 1 (HTLV-1) antibody, syphilis serum reaction
Patients with allergies to human serum albumin antibiotics, trypsin
Patients with eye infections
Patients with other retinal diseases (diabetic retinopathy, hypertensive retinopathy, vascular occlusion)
Patients with confirmed optic nerve atrophy
Patients with glaucoma who cannot control intraocular pressure
Patients with findings associated with myopic traction macular disease (apparent posterior macular tumor, vitreous macular traction, retinal separation, macular hole detachment, macular hole)
Patients with atrophy in all areas of the circle within 3 papilla diameter (4.5 mm) (9.0 mm in diameter) from the fovea
Patients with corrected visual acuity of control eye 0.08 or less
Patients with severe blood disorders, heart failure, liver disorders, and renal disorders
Patients diagnosed with malignant tumor within 5 years or patients requiring treatment
Pregnant women, lactating women, patients wishing to become pregnant during the trial period
Patients who cannot discontinue anticoagulants or antiplatelet drugs before the trial
Patients with drug addiction or alcoholism
Patients receiving treatment with vascular endothelial growth factor inhibitor or photodynamic therapy within 4 months prior to transplantation for test eye or 2 months for reference eye.
Patients who underwent eye surgery (excluding lens reconstruction) within 3 months before transplantation. In the case of cataract surgery, if 7 days or more have passed since surgery and postoperative inflammation is stable, registration is possible.